Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.

Harbeck N, Wrobel D, Zaiss M, Terhaag J, Guth D, Distelrath A, Zahn MO, Wuerstlein R, Lorenz A, Bartsch R, Breitenstein U, Schwitter M, Balic M, Jackisch C, Müller V, Rinnerthaler G, Schmidt M, Zaman K, Schinköthe T, Resch A, Valenti R, Lüftner D.

Open source

DOI: 10.1159/000533657
Published: 2023-10-05
Container: Breast Care (Basel)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1159/000533657,
  title = {Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.},
  author = {Harbeck N and  Wrobel D and  Zaiss M and  Terhaag J and  Guth D and  Distelrath A and  Zahn MO and  Wuerstlein R and  Lorenz A and  Bartsch R and  Breitenstein U and  Schwitter M and  Balic M and  Jackisch C and  Müller V and  Rinnerthaler G and  Schmidt M and  Zaman K and  Schinköthe T and  Resch A and  Valenti R and  Lüftner D.},
  year = {2024},
  journal = {Breast Care (Basel)},
  doi = {10.1159/000533657},
  url = {https://doi.org/10.1159/000533657}
}

RIS

TY  - JOUR
TI  - Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.
AU  - Harbeck N
AU  -  Wrobel D
AU  -  Zaiss M
AU  -  Terhaag J
AU  -  Guth D
AU  -  Distelrath A
AU  -  Zahn MO
AU  -  Wuerstlein R
AU  -  Lorenz A
AU  -  Bartsch R
AU  -  Breitenstein U
AU  -  Schwitter M
AU  -  Balic M
AU  -  Jackisch C
AU  -  Müller V
AU  -  Rinnerthaler G
AU  -  Schmidt M
AU  -  Zaman K
AU  -  Schinköthe T
AU  -  Resch A
AU  -  Valenti R
AU  -  Lüftner D.
PY  - 2024
JO  - Breast Care (Basel)
DO  - 10.1159/000533657
UR  - https://doi.org/10.1159/000533657
ER  -

APA

N, H., D, W., M, Z., J, T., D, G., A, D., MO, Z., R, W., A, L., R, B., U, B., M, S., M, B., C, J., V, M., G, R., M, S., K, Z., T, S., A, R., R, V., & D., L. (2024). Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.. Breast Care (Basel). https://doi.org/10.1159/000533657

Source records

europe-pmc · retrieved 2026-09-26T22:50:07.235Z